Will Latanoprost Be the 'Wonder' Drug of the '90s for the Treatment of Glaucoma?

Higginbotham, Eve J.

doi:10.1001/archopht.1996.01100140206015

Cited by 14 publications

(14 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Starting in the 1990s, the introduction of topical prostaglandins (PGs), i.e. latanoprost (Xalatan, Pharmacia, Kalmazoo, MI, USA), unoprostone isopropyl (Rescula, Ciba Vision, Duluth, GA, USA), bimatoprost (Lumigan, Allergan, Irvine, CA, USA) and travoprost (Travatan, Alcon Laboratories, Ft Worth, TX, USA), provided a new class of topical ocular hypotensive drugs for clinical management of the glaucomas in humans 3–8 . These agents offer the advantage of single drop administration daily, their ocular hypotensive effects are additive to other glaucoma drugs, and they avoid the cardiopulmonary effects of the beta blockers 1 .…”

Section: Introductionmentioning

confidence: 99%

“…PGs have been shown to reduce IOP in a number of animal species including dogs, cats, nonhuman primates and rabbits by mainly increasing uveoscleral aqueous humor outflow; however, the amount of IOP reduction can vary by the individual PG as well as the species 12–19 . In humans reductions in IOP occur with PGE and PGF analogs 3,5 and similar IOP declines occur in the normal and glaucomatous dog after topical PGA 2 isopropyl ester and PGF 2µ isopropyl ester, but not after PGA 2 17,18 …”

Section: Introductionmentioning

confidence: 99%

“…latanoprost (Xalatan, Pharmacia, Kalmazoo, MI, USA), unoprostone isopropyl (Rescula, Ciba Vision, Duluth, GA, USA), bimatoprost (Lumigan, Allergan, Irvine, CA, USA) and travoprost (Travatan, Alcon Laboratories, Ft Worth, TX, USA), provided a new class of topical ocular hypotensive drugs for clinical management of the glaucomas in humans. [3][4][5][6][7][8] These agents offer the advantage of single drop administration daily, their ocular hypotensive effects are additive to other glaucoma drugs, and they avoid the cardiopulmonary effects of the beta blockers. 1 Their primary adverse effects with chronic use in humans, nonhuman primates and rabbits are increased iridal pigmentation, hypertrichosis and pigmentation of the eyelashes.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of different dose schedules of travoprost on intraocular pressure and pupil size in the glaucomatous Beagle

Gelatt

MacKay

2004

Veterinary Ophthalmology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of different dose schedules of travoprost on intraocular pressure and pupil size in the glaucomatous Beagle

Gelatt

MacKay

2004

Veterinary Ophthalmology

View full text Add to dashboard Cite

show abstract

“…In humans, reductions in IOP occur with PGE and PGF analog (2,26), and similar IOP declines occur in the normal and glaucomatous dog after the administration of topical PGA 2 isopropyl ester and PGF 2ϰ isopropyl ester, but not after PGA 2 (23). In normal and experimental glaucomatous nonhuman primates, unoprostone lowered IOP-but not as long, nor as low, as after latanoprost (17).…”

Section: Introductionmentioning

confidence: 86%

“…The introduction of topical prostaglandins in America, i.e., latanoprost (Xalatan,™ Pharmacia, Kalmazoo, MI), bimatoprost (Lumigan,™ Allergan, Irvine, CA) and travoprost (Travatan,™ Alcon Laboratories, Ft. Worth, TX) in the 1990s provided a new class of topical ocular hypotensive drugs for the clinical management of the glaucomas in humans (1)(2)(3)(4)(5)(6)(7). These agents offer the advantage of single-drop administration daily; their ocular hypotensive effects are additive to other glaucoma drugs; and they avoid the cardiopulmonary effects of the beta blockers (1,8).…”

Section: Introductionmentioning

confidence: 99%

Effect of Different Dose Schedules of 0.15% Unoprostone Isopropyl on Intraocular Pressure and Pupil Size in the Glaucomatous Beagle

Gelatt¹,

MacKay²,

Dashiell³

et al. 2004

J Ocul Pharmacol Ther

View full text Add to dashboard Cite

The changes in intraocular pressure (IOP) and pupil size (PS) after instillations of 0.15% unoprostone isopropyl (Rescula, Novartis Ophthalmics, Duluth, GA) were investigated in the spontaneous glaucoma Beagle model. From the first-day baseline IOP of 27.3 Ϯ 3.2 mmHg placebo eye and 32.8 Ϯ 5.1 mmHg control eye, the mean Ϯ standard error of the mean (SEM) diurnal changes after 0.15% unoprostone, at 8 AM once-daily for the next 4 days, were 15.5 Ϯ 1.3 mmHg, 14.7 Ϯ 1.9 mmHg, 16.1 Ϯ 1.1 mmHg, and 17.0 Ϯ 1.5 mmHg, respectively, and were significantly different from the control eye. After 0.15% unoprostone was instilled at 8 PM, the mean Ϯ SEM baseline changes from the baseline IOP (insert drug eye 9 AM) in the drug eyes were 5.9 Ϯ 2.5 mmHg, 5.2 Ϯ 4.1 mmHg, 9.7 Ϯ 2.5 mmHg, and 3.6 Ϯ 3.6 mmHg, respectively. When 0.15% unoprostone was instilled twice-daily, the mean Ϯ SEM baseline IOP (insert drug eye 9 AM) changes were 13.6 Ϯ 0.7 mmHg, 13.9 Ϯ 1.4 mmHg, 11.3 Ϯ 1.0 mmHg, and 9.3 Ϯ 1.4 mmHg, respectively, and were significantly different from the control eyes. Miosis occurred within 2 hours and lasted several hours. Unoprostone isopropyl instilled once-daily (AM or PM), as well as twice-daily, produces significant decreases in IOP and PS in the glaucomatous Beagle.

show abstract

β-Blocker–Induced Complications and the Patient With Glaucoma

Stewart¹,

Garrison²

1998

Arch Intern Med

View full text Add to dashboard Cite

Primary open-angle glaucoma is a condition associated with an elevated intraocular pressure (IOP) that is defined as optic degeneration with a slowly progressive deterioration of the visual field that may lead to blindness. More than 1 million Americans are being treated for glaucoma, and 80,000 are legally blind as a result of the disease. Glaucoma has its highest prevalence among the elderly population, with an incidence of approximately 1% in those older than 60 years, 3% in those between the ages of 70 and 80 years, and more than 9% in those older than 80 years. Treatment is directed at lowering high ocular pressures. The initial treatment, in most cases topical therapy with a beta-adrenergic blocking agent, reduces the IOP to help preserve sight. But such topical agents may also have adverse systemic effects on cardiac, pulmonary, central nervous system (CNS), and endocrine functions.

show abstract

Will Latanoprost Be the 'Wonder' Drug of the '90s for the Treatment of Glaucoma?

Cited by 14 publications

References 9 publications

Effect of different dose schedules of travoprost on intraocular pressure and pupil size in the glaucomatous Beagle

Effect of different dose schedules of travoprost on intraocular pressure and pupil size in the glaucomatous Beagle

Effect of Different Dose Schedules of 0.15% Unoprostone Isopropyl on Intraocular Pressure and Pupil Size in the Glaucomatous Beagle

β-Blocker–Induced Complications and the Patient With Glaucoma

Contact Info

Product

Resources

About